Connor, Clark & Lunn Investment Management Ltd. Pmv Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $21.8 Billion
- Q1 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 433,853 shares of PMVP stock, worth $681,149. This represents 0.0% of its overall portfolio holdings.
Number of Shares
433,853
Previous 185,123
134.36%
Holding current value
$681,149
Previous $573,000
28.62%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PMVP
# of Institutions
106Shares Held
45.5MCall Options Held
2KPut Options Held
600-
Orbimed Advisors LLC San Diego, CA6.48MShares$10.2 Million0.25% of portfolio
-
Arrow Mark Colorado Holdings LLC Denver, CO3.2MShares$5.02 Million0.07% of portfolio
-
Black Rock Inc. New York, NY3.11MShares$4.88 Million0.0% of portfolio
-
Euclidean Capital LLC New York, NY2.63MShares$4.13 Million0.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.45MShares$3.85 Million0.0% of portfolio
About PMV Pharmaceuticals, Inc.
- Ticker PMVP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,622,600
- Market Cap $71.6M
- Description
- PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...